

Educational Resources for Pathologists and Multi-Disciplinary Teams on Biomarker Testing to Advance Personalized Healthcare

PD-L1 in Triple Negative Breast Cancer

HER2 in Breast Cancer and
Gastroesophageal Adenocarcinoma

EGFR, ALK, ROS1 in Non-Small Cell
Lung Cancer

PD-L1 in Metastatic Urothelial Carcinoma
and Non-Small Cell Lung Cancer

Tumor Agnostic Markers Including
NTRK, TMB, and MSI

Emerging Technologies Including
Next Generation Sequencing (NGS)

**PLEASE REACH OUT TO YOUR LOCAL BIOMARKER
TESTING TEAM SPECIALIST FOR MORE INFORMATION AT:**

GneBTT-d@gene.com

Genentech

A Member of the Roche Group